These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15102583

  • 1. Novel antipsychotics in schizophrenia.
    Mortimer AM.
    Expert Opin Investig Drugs; 2004 Apr; 13(4):315-29. PubMed ID: 15102583
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Atypical antipsychotic agents: a critical review.
    Worrel JA, Marken PA, Beckman SE, Ruehter VL.
    Am J Health Syst Pharm; 2000 Feb 01; 57(3):238-55. PubMed ID: 10674777
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors.
    Li X, Ma S.
    Curr Drug Targets; 2013 Jul 01; 14(8):899-918. PubMed ID: 23701299
    [Abstract] [Full Text] [Related]

  • 6. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb 01; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 7. Novel targets for drugs in schizophrenia.
    Stone JM, Pilowsky LS.
    CNS Neurol Disord Drug Targets; 2007 Aug 01; 6(4):265-72. PubMed ID: 17691983
    [Abstract] [Full Text] [Related]

  • 8. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP.
    J Psychopharmacol; 2004 Sep 01; 18(3):340-5. PubMed ID: 15358977
    [Abstract] [Full Text] [Related]

  • 9. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY, Li Z, Kaneda Y, Ichikawa J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct 01; 27(7):1159-72. PubMed ID: 14642974
    [Abstract] [Full Text] [Related]

  • 10. Conventional versus novel antipsychotics: changing concepts and clinical implications.
    Remington G, Chong SA.
    J Psychiatry Neurosci; 1999 Nov 01; 24(5):431-41. PubMed ID: 10586534
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.
    Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C.
    CNS Drugs; 2006 Nov 01; 20(5):389-409. PubMed ID: 16696579
    [Abstract] [Full Text] [Related]

  • 13. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S, Seeman P.
    Am J Psychiatry; 2001 Mar 01; 158(3):360-9. PubMed ID: 11229973
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Does loxapine have "atypical" properties? Clinical evidence.
    Glazer WM.
    J Clin Psychiatry; 1999 Mar 01; 60 Suppl 10():42-6. PubMed ID: 10340686
    [Abstract] [Full Text] [Related]

  • 18. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R.
    Psychopharmacology (Berl); 1998 Jan 01; 135(2):119-26. PubMed ID: 9497016
    [Abstract] [Full Text] [Related]

  • 19. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics.
    Meltzer HY.
    J Clin Psychopharmacol; 1995 Feb 01; 15(1 Suppl 1):2S-3S. PubMed ID: 7730497
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.